NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 42 filers reported holding NABRIVA THERAPEUTICS PLC in Q2 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $469,000 | -49.7% | 321,033 | -7.0% | 0.00% | -50.0% |
| Q3 2018 | $932,000 | -23.6% | 345,103 | -1.5% | 0.00% | -33.3% |
| Q2 2018 | $1,220,000 | -31.6% | 350,438 | -1.2% | 0.00% | -40.0% |
| Q1 2018 | $1,784,000 | +167.1% | 354,763 | +217.4% | 0.01% | +150.0% |
| Q4 2017 | $668,000 | -23.5% | 111,763 | +4.8% | 0.00% | -33.3% |
| Q3 2017 | $873,000 | -25.3% | 106,625 | +2.5% | 0.00% | -25.0% |
| Q2 2017 | $1,168,000 | – | 104,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
| Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
| IFP Advisors, Inc | 0 | $0 | 0.00% |